Allianz Asset Management Gmb H Cytom X Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$3.61 - $8.6 $139,562 - $332,476	-38,660 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$5.17 - $8.91 $537,633 - $926,559	-103,991 Reduced 72.9%	38,660 $321,000
Q3 2019 Nov 13, 2019	SELL	$7.38 - $12.25 $280,454 - $465,524	-38,002 Reduced 21.04%	142,651 $1.07 Million
Q2 2019 Aug 08, 2019	SELL	$9.35 - $11.41 $1.43 Million - $1.74 Million	-152,747 Reduced 45.81%	180,653 $2.03 Million
Q1 2019 May 13, 2019	BUY	$9.5 - $19.16 $306,603 - $618,369	32,274 Added 10.72%	333,400 $3.58 Million
Q4 2018 Feb 14, 2019	SELL	$12.69 - $18.61 $1.84 Million - $2.7 Million	-145,097 Reduced 32.52%	301,126 $4.54 Million
Q3 2018 Nov 13, 2018	BUY	$18.04 - $26.41 $1.67 Million - $2.45 Million	92,693 Added 26.22%	446,223 $8.26 Million
Q2 2018 Aug 13, 2018	BUY	$21.38 - $29.68 $6.3 Million - $8.75 Million	294,791 Added 501.87%	353,530 $8.08 Million
Q1 2018 May 14, 2018	BUY	$21.76 - $34.22 $87,823 - $138,111	4,036 Added 7.38%	58,739 $1.67 Million
Q4 2017 Feb 13, 2018	SELL	$19.0 - $23.09 $1,615 - $1,962	-85 Reduced 0.16%	54,703 $1.16 Million
Q3 2017 Nov 13, 2017	BUY	$13.53 - $18.17 $741,281 - $995,497	54,788	54,788 $995,000

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.